US 12,168,050 B2
Compositions comprising a norovirus nucleic acid and methods of use thereof
Susanne Rauch, Tübingen (DE); Kim Ellen Schwendt, Dettenhausen (DE); and Benjamin Petsch, Tübingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on Sep. 8, 2021, as Appl. No. 17/469,313.
Application 17/469,313 is a division of application No. 16/098,840, granted, now 11,141,474, previously published as PCT/EP2017/060673, filed on May 4, 2017.
Claims priority of application No. PCT/EP2016/060115 (WO), filed on May 4, 2016.
Prior Publication US 2021/0401966 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/125 (2006.01); A61K 9/00 (2006.01); A61P 31/12 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/125 (2013.01) [A61K 9/0019 (2013.01); A61P 31/12 (2018.01); C07K 14/005 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); C12N 2770/16034 (2013.01)] 28 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising at least one artificial RNA molecule and at least three different RNA coding regions encoding three different Norovirus VP1 polypeptides, said coding regions each encoding a different GII.4 VP1 polypeptide and having at least 90% identity to the polypeptide coding sequence of SEQ ID NOs: 39713-39721 or 39726-39738, wherein the at least one artificial RNA molecule comprises at least one heterologous 5′ and/or 3′ untranslated region (UTR).